Spartalis Michael, Nakajima Kenzaburo, Zweiker David, Spartalis Eleftherios, Iliopoulos Dimitrios C, Siasos Gerasimos
Arrhythmia Unit, IRCCS San Raffaele Scientific Institute, San Raffaele University Hospital, Milan, Italy.
Laboratory of Experimental Surgery and Surgical Research 'N. S. Christeas', Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Cardiol Ther. 2021 Dec;10(2):313-324. doi: 10.1007/s40119-021-00225-7. Epub 2021 Jun 15.
Despite constant breakthroughs in heart failure (HF) therapy, the population of HF patients resume to grow and is linked to increased mortality and morbidity. Ventricular arrhythmias (VA) are one of the leading causes of mortality in HF subjects. Implantable cardioverter-defibrillators (ICDs) are currently the gold standard in treatment, preventing arrhythmic sudden cardiac death (SCD) episodes. However, the death rates related to HF remain elevated, as not all HF subjects benefit equally. Cardiac resynchronization therapy (CRT) has emerged as a novel approach for HF patients. These devices have been thoroughly investigated in major randomized controlled studies but continue to be underutilized in various countries. This review discusses the use of ICD in HF populations on top of treatments.
尽管心力衰竭（HF）治疗不断取得突破，但HF患者的数量仍在持续增长，且与死亡率和发病率的增加相关。室性心律失常（VA）是HF患者死亡的主要原因之一。植入式心脏复律除颤器（ICD）是目前治疗的金标准，可预防心律失常性心源性猝死（SCD）发作。然而，与HF相关的死亡率仍然居高不下，因为并非所有HF患者都能平等受益。心脏再同步治疗（CRT）已成为治疗HF患者的一种新方法。这些设备已在主要的随机对照研究中得到充分研究，但在各个国家仍未得到充分利用。本综述讨论了在HF人群中除其他治疗外使用ICD的情况。
